KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals has reported Total Non-Current Liabilities over the past 9 years, most recently at $2.8 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 15.5% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 15.5%, while the annual FY2025 figure was $2.8 billion, 15.5% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $2.8 billion at Amneal Pharmaceuticals, roughly flat from $2.8 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $2.9 billion in Q2 2021 and troughed at $2.3 billion in Q1 2025.
  • A 5-year average of $2.7 billion and a median of $2.8 billion in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 12.44% in 2024 and later increased 15.86% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $2.9 billion in 2021, then decreased by 1.42% to $2.8 billion in 2022, then fell by 9.62% to $2.6 billion in 2023, then dropped by 5.79% to $2.4 billion in 2024, then grew by 15.5% to $2.8 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for AMRX at $2.8 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.4 billion in Q2 2025.